哌罗匹隆与利培酮对首发精神分裂症患者社会功能影响的对比分析

Comparative Analysis on Effect of Perospirone and Risperidone on Social Functions in Patients with First-episode Schizophrenia

目的:比较哌罗匹隆与利培酮对首发精神分裂症患者社会功能的影响。方法:收集2015年10月—2017年10月就诊于我院的首发精神分裂症患者122例,按照治疗方法不同分为A组和B组,各61例。A组用哌罗匹隆(起始4 mg/d,加至12~48 mg/d)治疗,B组用利培酮(起始1 mg/d,加至3~6 mg/d)治疗,比较两组临床疗效、阳性和阴性症状量表(PANSS)评分、不良反应量表(TESS)评分、社会功能缺陷筛选量表(SDSS)评分。结果:两组总有效率比较,差异无统计学意义(P> 0.05);治疗后两组PANSS评分、SDSS评分均较治疗前降低,差异有统计学意义(P <0.05);治疗后两组PANSS评分、SDSS评分比较,差异无统计学意义(P> 0.05);治疗后A组职业和工作、社会性退缩、兴趣关心、责任心和计划性评分低于B组,差异有统计学意义(P <0.05);A组内分泌改变、体质量增加发生率低于B组,差异有统计学意义(P <0.05)。结论 :哌罗匹隆、利培酮治疗首发精神分裂症的临床效果均显著,但哌罗匹隆的安全性更高,在改善社会功能缺陷方面优势更明显。

Objective:To compare the effect of perospirone and risperidone on the social functions of patients with first-episode schizophrenia.Methods:122 patients with first-episode schizophrenia admitted to our hospital from October 2015 to October 2017 were enrolled and divided into group A and group B according to different treatment methods,61 cases each.The patients in the group A were treated with perospirone(starting dose:4 mg/d,increased to 12~48 mg/d),and the patients in the group B were treated with risperidone(starting dose:1 mg/d,increased to 3~6 mg/d).The clinical efficacy,positive and negative symptom scale(PANSS)scores,adverse reaction scale(TESS)scores and social dysfunction screening scale(SDSS)scores were compared between the two groups.Results:There was no statistically significant difference in the total effective rate between the two groups(P>0.05).The PANSS scores and SDSS scores after treatment were lower than those before treatment in the two groups,with statistically significant differences(P<0.05).There were no statistically significant differences in PANSS scores and SDSS scores after treatment between the two groups(P>0.05).The occupation and work,social withdrawal,interest concern,responsibility and planned scores in the group A were lower than those in the group B,and the differences were statistically significant(P<0.05).The incidences of endocrine changes and body mass increase in the group A were lower than those in the group B,and the differences were statistically significant(P<0.05).Conclusion:Perospirone and risperidone have significant therapeutic effects on first-episode schizophrenia,but perospirone has higher safety and more obvious advantages in improving social dysfunction.